BRCA2 and ovarian cancer: The BRCA2 variant, rs11571833, on exon 27, results in a premature stop codon p. Lys3326*, removing the last 92 amino acids at the C terminus of BRCA2 and shown to be pathogenic in in vitro splicing assays[12] and associated with risk of breast, prostate and ovarian cancers[13,14].